Re: Biogen/Eisai Scrap Aducanumab
in response to
by
posted on
Mar 23, 2019 10:10AM
Koo,
From the cognition study description:
"In patients at least 70 years of age the MoCA is administrated at randomization, yearly, and at termination of the trial. Cognition assessment by MoCA is a pre-specified variable comparing change from baseline in both treatment groups, adjusted for age, education, and baseline MoCA score. Additionally, a subgroup of patients with MoCA score ≤25 will be analyzed separately."
I think the 467 is the number of patients in BETonMACE that are 70 or older and will receive baseline and annual MoCA. The 246 is the subset of those 467 with baseline MoCA of 25 or below. Sounds like the 246 will be a sub-group analyzed separately from the whole 467.
Median refers to the MoCA value at the halfway/midpoint of the observed values. So for the 467, the midpoint MoCA score is 25 with minimum and maximum scores of 7 and 30, respectively. For the 246, the midpoint MoCA score is 22 with minimum and maximum scores of 7 and 25, respectively. So half of each group will be above the median/midpoint value and half will be below the median/midpoint value.
BearDownAZ